These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11011337)

  • 1. Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension.
    Omvik P; Gerdts E; Myking OL; Lund-Johansen P
    Am Heart J; 2000 Oct; 140(4):624-30. PubMed ID: 11011337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
    Greve AM; Olsen MH; Bella JN; Lønnebakken MT; Gerdts E; Okin PM; Palmieri V; Boman K; Nieminen MS; Omvik P; Dahlöf B; Devereux RB; Wachtell K
    Am J Hypertens; 2012 Sep; 25(9):1017-23. PubMed ID: 22695506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [REGRESSION OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ESSENTIAL HYPERTENSION AND LONG-TERM THERAPY WITH LOSARTAN].
    Dotsenko SY; Tokarenko AA; Tokarenko II
    Lik Sprava; 2015; (7-8):17-21. PubMed ID: 27491145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis.
    Mitsuhashi H; Tamura K; Yamauchi J; Ozawa M; Yanagi M; Dejima T; Wakui H; Masuda S; Azuma K; Kanaoka T; Ohsawa M; Maeda A; Tsurumi-Ikeya Y; Okano Y; Ishigami T; Toya Y; Tokita Y; Ohnishi T; Umemura S
    Atherosclerosis; 2009 Nov; 207(1):186-90. PubMed ID: 19423110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitrendipine vs. captopril in essential hypertension: effects on circadian blood pressure and left ventricular hypertrophy.
    Machnig T; Henneke KH; Engels G; Pongratz G; Schmalzl M; Gellert J; Bachmann K
    Cardiology; 1994; 85(2):101-10. PubMed ID: 7954561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy).
    Gerdts E; Björnstad H; Devereux RB; Lund-Jhansen P; Davidsen ES; Omvik P
    Blood Press; 2006; 15(4):220-6. PubMed ID: 17060116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
    Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
    J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.
    Lund-Johansen P; Omvik P; Nordrehaug JE; White W
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S27-34. PubMed ID: 1378146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan.
    Avanza AC; El Aouar LM; Mill JG
    Arq Bras Cardiol; 2000 Feb; 74(2):103-17. PubMed ID: 10904284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
    Fogari R; Mugellini A; Destro M; Corradi L; Lazzari P; Zoppi A; Preti P; Derosa G
    Diabet Med; 2012 Jan; 29(1):24-31. PubMed ID: 21781149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A double ambulatory product (blood pressure and heart rate), mild arterial hypertension and left ventricular hypertrophy].
    Azevedo J; Arroja I; Jacques A; Santos I; Amado P; Marques JC; Araújo V
    Rev Port Cardiol; 1993; 12(7-8):663-73, 602. PubMed ID: 8352987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension].
    Tedesco MA; Ratti G; Aquino D; Caccavale A; Acitorio M; Rocereto A; Cosimi R; Coppolino P; Iarussi D; Iacono A
    Cardiologia; 1998 Jan; 43(1):53-9. PubMed ID: 9534293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic and 24-h blood pressure profile of amlodipine monotherapy.
    Ibrahim MM; el-Boghdadly B; Zaghloul SS
    J Hum Hypertens; 1996 Jul; 10(7):489-94. PubMed ID: 8880565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies.
    Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG
    Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome.
    Nashar K; Nguyen JP; Jesri A; Morrow JD; Egan BM
    Am J Hypertens; 2004 Jun; 17(6):477-82. PubMed ID: 15177518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Oikarinen L; Nieminen MS; Viitasalo M; Toivonen L; Jern S; Dahlöf B; Devereux RB; Okin PM;
    Hypertension; 2004 May; 43(5):1029-34. PubMed ID: 15037560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study].
    Krupicka J; Ceypová K; Kristenová P; Hauser T
    Vnitr Lek; 2008 Nov; 54(11):1031-8. PubMed ID: 19069675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.